These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 7713570)

  • 1. Immunotherapy of tuberculosis with Mycobacterium vaccae NCTC 11659.
    Stanford JL; Stanford CA
    Immunobiology; 1994 Oct; 191(4-5):555-63. PubMed ID: 7713570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does immunotherapy with heat-killed Mycobacterium vaccae offer hope for the treatment of multi-drug-resistant pulmonary tuberculosis?
    Stanford JL; Stanford CA; Grange JM; Lan NN; Etemadi A
    Respir Med; 2001 Jun; 95(6):444-7. PubMed ID: 11421500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis: a randomised controlled trial. Durban Immunotherapy Trial Group.
    Lancet; 1999 Jul; 354(9173):116-9. PubMed ID: 10408487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind placebo-controlled trial of Mycobacterium vaccae immunotherapy for tuberculosis in KwaZulu, South Africa, 1991-97.
    Mayo RE; Stanford JL
    Trans R Soc Trop Med Hyg; 2000; 94(5):563-8. PubMed ID: 11132390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis.
    Stanford J; Stanford C; Grange J
    Front Biosci; 2004 May; 9():1701-19. PubMed ID: 14977580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunotherapeutic effect of Mycobacterium vaccae on multi-drug resistant pulmonary tuberculosis].
    Luo Y; Lu S; Guo S
    Zhonghua Jie He He Hu Xi Za Zhi; 2000 Feb; 23(2):85-8. PubMed ID: 11778496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy with Mycobacterium vaccae combined with second line chemotherapy in drug-resistant abdominal tuberculosis.
    Prior JG; Khan AA; Cartwright KA; Jenkins PA; Stanford JL
    J Infect; 1995 Jul; 31(1):59-61. PubMed ID: 8522836
    [No Abstract]   [Full Text] [Related]  

  • 9. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The immunotherapeutic effect of Mycobacterium vaccae vaccine on initially treated pulmonary tuberculosis].
    Luo Y;
    Zhonghua Jie He He Hu Xi Za Zhi; 2001 Jan; 24(1):43-7. PubMed ID: 11802939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative study of immunizing and delayed hypersensitivity eliciting antigens of Mycobacterium leprae, M. tuberculosis, M. vaccae, and M. bovis (BCG).
    Sinha S; Sreevatsa ; Gupta SK; Sengupta U
    Int J Lepr Other Mycobact Dis; 1987 Mar; 55(1):42-53. PubMed ID: 2435824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of a five-dose series of inactivated Mycobacterium vaccae vaccination for the prevention of HIV-associated tuberculosis.
    Waddell RD; Chintu C; Lein AD; Zumla A; Karagas MR; Baboo KS; Habbema JD; Tosteson AN; Morin P; Tvaroha S; Arbeit RD; Mwinga A; von Reyn CF
    Clin Infect Dis; 2000 Jun; 30 Suppl 3():S309-15. PubMed ID: 10875806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy.
    Jenkins PA; Campbell IA; Banks J; Gelder CM; Prescott RJ; Smith AP
    Thorax; 2008 Jul; 63(7):627-34. PubMed ID: 18250184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A brief history of tuberculosis in Iran during the 19th and 20th centuries.
    Azizi MH; Bahadori M
    Arch Iran Med; 2011 May; 14(3):215-9. PubMed ID: 21529117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tuberculosis II: the failure of the BCG vaccine.
    Maes RF
    Med Hypotheses; 1999 Jul; 53(1):32-9. PubMed ID: 10499822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy with Mycobacterium vaccae as an addition to chemotherapy for the treatment of pulmonary tuberculosis under difficult conditions in Africa.
    Onyebujoh PC; Abdulmumini T; Robinson S; Rook GA; Stanford JL
    Respir Med; 1995 Mar; 89(3):199-207. PubMed ID: 7746913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diagnosis and treatment of mycobacterial infections in patients with HIV/AIDS].
    Pulido F; Iribarren JA; Kindelan JM; Moreno S
    Enferm Infecc Microbiol Clin; 1998; 16 Suppl 1():20-8. PubMed ID: 9859616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A longitudinal study of per cent agalactosyl IgG in tuberculosis patients receiving chemotherapy, with or without immunotherapy.
    Rook GA; Onyebujoh P; Wilkins E; Ly HM; al Attiyah R; Bahr G; Corrah T; Hernandez H; Stanford JL
    Immunology; 1994 Jan; 81(1):149-54. PubMed ID: 8132212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased protection against bovine tuberculosis in the brushtail possum (Trichosurus vulpecula) when BCG is administered with killed Mycobacterium vaccae.
    Skinner MA; Keen DL; Parlane NA; Yates GF; Buddle BM
    Tuberculosis (Edinb); 2002; 82(1):15-22. PubMed ID: 11914058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of multi-drug-resistant tuberculosis in mice with DNA vaccines alone or in combination with chemotherapeutic drugs.
    Liang Y; Wu X; Zhang J; Yang Y; Wang L; Bai X; Yu Q; Li N; Li Z
    Scand J Immunol; 2011 Jul; 74(1):42-6. PubMed ID: 21352251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.